These Analysts Boost Their Forecasts On Abbott Laboratories After Better-Than-Expected Earnings

Core Viewpoint - Abbott Laboratories reported better-than-expected first-quarter adjusted EPS results, showcasing strong sales growth and effective management strategies [1][2]. Financial Performance - First-quarter sales reached $10.36 billion, reflecting a year-over-year increase of 7.2$10.40 billion [1]. - Adjusted EPS for the first quarter was $1.09, surpassing the consensus of$1.07 and management's guidance of $1.05-$1.09 [1]. Future Outlook - For the second quarter of 2025, Abbott Laboratories anticipates adjusted EPS in the range of $1.23-$1.27, compared to the consensus estimate of $1.25 [2]. - Following the earnings announcement, Abbott's shares increased by 0.9$130.81 [2]. Analyst Ratings and Price Targets - Jefferies analyst Matthew Taylor maintained a Hold rating and raised the price target from $135 to$137 [7]. - Stifel analyst Rick Wise maintained a Buy rating and increased the price target from $135 to$145 [7]. - Barclays analyst Matt Miksic maintained an Overweight rating and raised the price target from $158 to$159 [7].